Cocrystal Pharma Inc (COCP) Stock Price, Quote & News

Company Profile

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. It employs structure-based technologies to create antiviral drugs including influenza virus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as norovirus, respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a cl...

Industry: Biotechnology

Sector: Healthcare

Phone: 877 262 7123

Website: www.cocrystalpharma.com

Address:

19805 North Creek Parkway, Bothell, United States

KevinonX46101663 Aug. 3 at 2:51 PM

$COCP My name is Kevin and I agree big news is coming look at the 2 million share volume on Friday but sadly I don't want to admit the truth unfortunately for me I don't own it anymore and super jealous that my past thoughts are coming to fruition DOD BARDA is a big deal and it is non dilutive funding & is happening in days but in the meantime sorry for high jacking the thread I can't help pouring out my pain I lost a lot ** hey check out my past bull posts from nov 2023 you can see I was 2 yrs too early

0 · Reply

MarkPumps Aug. 3 at 2:48 PM

$COCP Wainwright is trading shares back and forth to create volume but baggies will still get dumped on. Never learn

0 · Reply

MarkPumps Aug. 3 at 2:47 PM

$COCP Your opinion does not matter on this stock. You are down 99% with Mark @ms101 @momo2021 @elon_musk22

0 · Reply

MarkPumps Aug. 3 at 2:19 PM

$COCP everyone knows the news the presentation. Its wainwright trying to make it seem important so they can dilute as usual. If someone wanted in they didn't need to do it on Friday.

2 · Reply

Ultimate1trader Aug. 3 at 2:05 PM

$COCP saw an unusually high trading volume of ~2 million shares last Friday, far above its typical daily average, something is definitely going on. That kind of volume spike in a low-float biotech like COCP usually signals either incoming news, insider awareness, or speculative buildup ahead of a potential catalyst.

0 · Reply

MarkPumps Aug. 3 at 11:43 AM

$COCP a new baggy has been created.

0 · Reply

MarkPumps Aug. 3 at 11:43 AM

$COCP lol mark came back really angry on @elon_musk22 after @momo2021 was banned for pumping. Get ready for a wainwright offering

0 · Reply

Bullishtrading25 Aug. 3 at 3:18 AM

$COCP Wow, it’s impressive how you jump to conclusions with so little info. Maybe next time, try actually knowing what you’re talking about before throwing around insults—you might look less clueless.

0 · Reply

elon_musk22 Aug. 3 at 3:16 AM

$COCP $EPIX Kevin was pitching mrna from 100 to 20 if you are long down 85% wiped out on big ones ouchie but watch out he is in the know for the boogy man Lmfaooooo and everyone is ms101 lolololomfaooo

0 · Reply

elon_musk22 Aug. 3 at 3:15 AM

$EPIX $COCP poor Kevin I am sure you picked some failures hey Kevin all your picks are failures LMfaoooo

0 · Reply

Cocrystal Pharma to Present Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference

Jun 5, 2025, 8:00 AM EDT - 2 months ago

Cocrystal Pharma's Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference

May 29, 2025, 8:00 AM EDT - 2 months ago

Cocrystal Pharma's Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain

May 28, 2025, 8:00 AM EDT - 2 months ago

Cocrystal Pharma to Participate in Noble Capital Markets' 2025 Emerging Growth Virtual Equity Conference

May 15, 2025, 8:00 AM EDT - 2 months ago

Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Apr 24, 2025, 8:00 AM EDT - 3 months ago

Cocrystal Pharma's Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants

Apr 16, 2025, 8:00 AM EDT - 3 months ago

Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference

Mar 31, 2025, 8:00 AM EDT - 4 months ago

Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Mar 6, 2025, 8:00 AM EST - 5 months ago

Cocrystal Pharma to Participate in a Fireside Chat at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025

Dec 31, 2024, 2:21 PM EST - 7 months ago

Dow Dips Over 100 Points; Cocrystal Pharma Shares Slide

Dec 31, 2024, 8:00 AM EST - 7 months ago

Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344

Aug 19, 2024, 4:05 PM EDT - 1 year ago

Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences

Aug 15, 2024, 3:00 PM EDT - 1 year ago

CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event

May 13, 2024, 8:00 AM EDT - 1 year ago

Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

May 1, 2024, 8:00 AM EDT - 1 year ago

Enrollment Completed in Phase 2a Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza

Mar 28, 2024, 8:00 AM EDT - 1 year ago

Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Mar 19, 2024, 8:00 AM EDT - 1 year ago

Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A

Mar 5, 2024, 8:30 AM EST - 1 year ago

Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap

Dec 6, 2023, 8:00 AM EST - 1 year ago

Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A

Nov 29, 2023, 8:00 AM EST - 1 year ago

Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

Nov 27, 2023, 8:00 AM EST - 1 year ago

Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023

Nov 9, 2023, 8:00 AM EST - 1 year ago

Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

Oct 31, 2023, 8:00 AM EDT - 1 year ago

Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference

Apr 10, 2023, 8:30 AM EDT - 2 years ago

Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Mar 22, 2023, 8:00 AM EDT - 2 years ago

Cocrystal Pharma to Highlights Progress with Its Antiviral Portfolio at the Virtual Investor Summit on March 29, 2023

Jan 26, 2023, 8:00 AM EST - 2 years ago

Cocrystal Pharma Announces Participation in Virtual Investor Events

Jan 23, 2023, 9:00 AM EST - 2 years ago

Cocrystal Pharma Discusses Clinical Progress and Significance of Its Novel Antiviral Therapeutics Pipeline with The Stock Day Podcast

Dec 1, 2022, 4:05 PM EST - 2 years ago

Cocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment for Pandemic and Seasonal Influenza A at the World Antiviral Congress 2022

Nov 17, 2022, 8:00 AM EST - 2 years ago

Cocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A

Nov 1, 2022, 4:05 PM EDT - 2 years ago

Cocrystal Pharma Granted European Patent Covering Oral Antiviral Candidate CC-42344 in Combination with Another Antiviral Agent for the Treatment of Influenza

Oct 26, 2022, 8:00 AM EDT - 3 years ago

Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344

Oct 5, 2022, 8:00 AM EDT - 3 years ago

Cocrystal Pharma to Present at the Dawson James Securities 2022 Small Cap Growth Conference

Oct 3, 2022, 4:05 PM EDT - 3 years ago

Cocrystal Pharma Announces a 1-for-12 Reverse Stock Split

Aug 8, 2022, 8:00 AM EDT - 3 years ago

Cocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344

Aug 3, 2022, 9:00 AM EDT - 3 years ago

Cocrystal Pharma Discusses Therapeutic Platform Applications and Progress with The Stock Day Podcast

May 18, 2022, 8:00 AM EDT - 3 years ago

Cocrystal Pharma to Present at the H.C. Wainwright Global Investment Conference

May 11, 2022, 8:00 AM EDT - 3 years ago

Cocrystal Pharma Reports First Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs and Milestones

Apr 19, 2022, 8:00 AM EDT - 3 years ago

Cocrystal Pharma to Present at the Life Science Innovation Northwest 2022 Conference

Apr 12, 2022, 11:08 AM EDT - 3 years ago

Cocrystal Pharma Posts Favorable Preliminary Data From Influenza A Antiviral Candidate Trial

Apr 12, 2022, 8:00 AM EDT - 3 years ago

Cocrystal Pharma Reports Favorable Preliminary Data from Phase 1 Initial Cohorts with CC-42344, a Novel, Broad-Spectrum Influenza A antiviral

Mar 23, 2022, 4:05 PM EDT - 3 years ago

Cocrystal Pharma Reports 2021 Financial Results and Provides Updates on Development Programs and Milestones

Mar 22, 2022, 8:00 AM EDT - 3 years ago

Cocrystal Pharma to Participate in the Maxim Group 2022 Virtual Growth Conference

Mar 10, 2022, 8:00 AM EST - 3 years ago

Cocrystal Pharma Initiates Enrollment in Phase 1 Influenza A Study with Novel, Broad-Spectrum, Orally Administrated Antiviral CC-42344

Jan 27, 2022, 12:22 PM EST - 3 years ago

Cocrystal Pharma To Develop Additional Two Antiviral Drug Candidates For COVID-19

Jan 27, 2022, 8:00 AM EST - 3 years ago

Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates for its COVID-19 Oral Drug Program

Jan 6, 2022, 8:00 AM EST - 3 years ago

Cocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19 Antiviral CDI-45205

Dec 22, 2021, 11:43 AM EST - 3 years ago

Cocrystal's COVID-19 Antiviral Candidate Shows Potency Against Omicron Variant

Dec 22, 2021, 8:00 AM EST - 3 years ago

Cocrystal Pharma's COVID-19 Oral and Intranasal/Pulmonary Protease Inhibitors Exhibit Powerful In Vitro Potency Against the SARS-CoV-2 Omicron Variant

Dec 2, 2021, 8:00 AM EST - 3 years ago

Cocrystal Pharma to Discuss Progress with COVID-19 Antiviral Programs and Clinical Strategy During Noble Capital Markets' Channelchek Virtual Roadshow

KevinonX46101663 Aug. 3 at 2:51 PM

0 · Reply

MarkPumps Aug. 3 at 2:48 PM

$COCP Wainwright is trading shares back and forth to create volume but baggies will still get dumped on. Never learn

0 · Reply

MarkPumps Aug. 3 at 2:47 PM

$COCP Your opinion does not matter on this stock. You are down 99% with Mark @ms101 @momo2021 @elon_musk22

0 · Reply

MarkPumps Aug. 3 at 2:19 PM

$COCP everyone knows the news the presentation. Its wainwright trying to make it seem important so they can dilute as usual. If someone wanted in they didn't need to do it on Friday.

2 · Reply

Ultimate1trader Aug. 3 at 2:05 PM

0 · Reply

MarkPumps Aug. 3 at 11:43 AM

$COCP a new baggy has been created.

0 · Reply

MarkPumps Aug. 3 at 11:43 AM

$COCP lol mark came back really angry on @elon_musk22 after @momo2021 was banned for pumping. Get ready for a wainwright offering

0 · Reply

Bullishtrading25 Aug. 3 at 3:18 AM

0 · Reply

elon_musk22 Aug. 3 at 3:16 AM

0 · Reply

elon_musk22 Aug. 3 at 3:15 AM

$EPIX $COCP poor Kevin I am sure you picked some failures hey Kevin all your picks are failures LMfaoooo

0 · Reply

elon_musk22 Aug. 3 at 3:13 AM

$COCP Kevin mark pumps Kevin magic din dinn bull mar lmfaooo Fred Hassan 👀 Kevin broke 🤡

0 · Reply

elon_musk22 Aug. 3 at 3:11 AM

$COCP the point is do your on research on this one Kevin is mentally ill &pumped for 3 yrs got wiped out and hates it actually working LMfaooo end of story

0 · Reply

elon_musk22 Aug. 3 at 3:09 AM

$COCP ask Kevin what happened to his $EPIX failed pump its 1 buck from 10 down 90 percent LMfaooo fraud looks like its 1

0 · Reply

elon_musk22 Aug. 3 at 3:07 AM

$COCP even funnier his posts on x pumped it for 3 yrs but lost it all now the deep pain he will never sleep lmfAOoooo

0 · Reply

elon_musk22 Aug. 3 at 3:05 AM

$COCP this is the #1 basher and here is his x posts LMFAOOOOO this stock is wall paper bankrupt

0 · Reply

elon_musk22 Aug. 3 at 3:03 AM

$COCP yes

0 · Reply

elon_musk22 Aug. 3 at 3:02 AM

$COCP exactly something in the works and Kevin is freaking lmfaooo

0 · Reply

elon_musk22 Aug. 3 at 3:02 AM

$COCP bribed hassan sounds like you are mad broke 🤡

0 · Reply

elon_musk22 Aug. 3 at 3:01 AM

$COCP nope don't let this fool convince you on anything read his x account he has lost money 100% of the time @Kevin46101663 don't take my word read it and cry and laugh he is some psycho path obsessed calling everyone marc etc lmfaooo

0 · Reply

elon_musk22 Aug. 3 at 2:58 AM

$COCP you will find out how wrong you are always again LMfaoooo

0 · Reply

elon_musk22 Aug. 3 at 2:58 AM

$COCP you will never be billionaire magic lmfaooo

0 · Reply

elon_musk22 Aug. 3 at 2:58 AM

$COCP one day when its too late u will understand biotech investing its not for novices lmfaooooooo additionally Lmfaoooo sam forgot more in the last hr than in your lifetime

0 · Reply

Market Cap	18.82M
Revenue (ttm)	0.00
Net Income (ttm)	-17.50M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	2,052,700
Avg Vol	68,388
Day's Range	N/A - N/A
Shares Out	10.17M
Stochastic %K	69%
Beta	2.06
Analysts	Strong Sell
Price Target	$8.00